Tolga Tanguler's departure as Chief Commercialization Officer of Alnylam Pharmaceuticals, Inc. was reported; the filing names no successor. As of November 6, 2026, Alnylam Pharmaceuticals, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 27, 2026 to November 5, 2026, naming 1 appointment and 1 departure (Form 8-K, November 5, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Alnylam Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Alnylam Pharmaceuticals, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-27 to 2026-11-05. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Alnylam Pharmaceuticals, Inc. files it.
Also on the record for Alnylam Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 9.5% of the class | 5%+ stakes | Source |
| October 30, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.03% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Capital Research Global Investors | 7.1% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Capital World Investors | 8.2% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.35% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| November 5, 2025 | Stake report, Schedule 13G/A, by FMR LLC | 12.8% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Alnylam Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Alnylam Pharmaceuticals, Inc. and the records around it.
Alnylam Pharmaceuticals, Inc. elsewhere on the record
Companies that share a holder
- Capital Research Global Investors also filed stake reports on 99 other companies: Royal Caribbean Cruises Ltd. (Oct 2026), Patria Investments Ltd. (Sep 2026), Arxis, Inc. (Aug 2026)
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Alnylam Pharmaceuticals, Inc.
Get an email when Alnylam Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Alnylam Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Alnylam Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alnylam Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-11-05 | Out | Chief Commercialization Officer | 8-K, 2026-11-05 | ||
| 2026-05-27 | In | 2026-06-01 | 8-K, 2026-05-27 |
Who leads Alnylam Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Commercialization Officer: Tolga Tanguler, departure reported (filed 2026-11-05). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Alnylam Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Commercialization Officer at Alnylam Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Chief Commercialization Officer at Alnylam Pharmaceuticals, Inc.Every change, in the filing's words
Departing: Tolga Tanguler, Chief Commercialization Officer
(b) On November 4, 2026, Alnylam Pharmaceuticals, Inc. (the "Company") announced that Tolga Tanguler will depart from his role as the Company's Executive Vice President, Chief Commercialization Officer in December 2026.
- Mr. Tanguler and the Company intend to enter into a written agreement not later than his separation date, which will contain the terms of his departure from the Company.
Appointed: Benjamin F. Cravatt, effective 2026-06-01
Effective as of June 1, 2026, the Board of Directors (the "Board") of Alnylam Pharmaceuticals, Inc. (the "Company"), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company's Board from ten to eleven and elected Benjamin F. Cravatt, Ph.D. to fill the newly created vacancy.
- Dr. Cravatt will serve as a Class III director with a term expiring at the annual meeting of stockholders to be held in 2028.
- Dr. Cravatt will also serve as a member of the Board's Science and Technology Committee.
- As a non-employee director, Dr. Cravatt will receive an annual cash retainer of $75,000.
- Following his election, Dr. Cravatt will be eligible to receive an annual equity award, in an aggregate amount to be determined by the Board upon recommendation of the People, Culture and Compensation Committee.
- The Company will also reimburse Dr. Cravatt for reasonable travel and other related expenses incurred in connection with his service on the Board.
- In addition, Dr. Cravatt will enter into an indemnification agreement with the Company consistent with the form of the existing indemnification agreement entered into between the Company and its non-employee directors.
Tools for this story
Each opens in a new tab, filled in for Alnylam Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.